Abstract 5372
Background
Alzheimer’s disease showed different connections with various types of cancers and, even, both are protecting from each other. Some studies attributed it to shared genetic backgrounds. One of the shared mutations is located on APOE4 gene, a risk factor in Alzheimer’s, and was connected to chemotherapy-related deterioration of cognitive functions in breast cancer patients. Our aim is to examine the addon effect of radiation therapy on the risk of death from Alzheimer’s disease.
Methods
We collected data from 13 USA cancer registries enrolled in Surveillance Epidemiology and End Results program using SEER*stat software. We enrolled patients diagnosed with head and neck cancers or brain cancers between 1992 and 2016. The event was defined as death due to Alzheimer’s disease following the cancer diagnosis. Moreover, we have calculated Multiple Primary Standardized Incidence Ratios and excess risk per 10,000 person-years, to estimate the change of risk following the diagnosis when compared to the general population. Besides, we calculated the effect of gender, age, and receiving radiation for cancer.
Results
Out of 142,541 patients (59,630 patients with brain malignancies, and 82,911 with head and neck malignancies), 151 died due to Alzheimer’s after more than 10 years following a cancer diagnosis; 20 had brain malignancies, and 131 had other head and neck malignancies. The risk of Alzheimer’s death increased significantly after more than 10 years of a cancer diagnosis with an O/E ratio of 1.35 and an excess risk of 2.72 per 10,000. The risk increased significantly among females (81 females and O/E was 1.4) and males (70 and O/E was 1.29). Alzheimer’s was the cause of death in 52 patients who received Radiation therapy, and 13 patients who received chemotherapy with O/Es of 1.45 and 1.59 respectively. The risk of disease-related mortality was high in patients older than 70 years, while patients who were diagnosed with cancer earlier did not show a significant increase in their risk of Alzheimer’s death than the general population.
Conclusions
Risk of Alzehimer’s-related mortality increases significantly among survivors of head and neck cancers and brain cancers. Further studies shall address the biological risk-modifying effects of aging, gender, and treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract